Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

Favipiravir study #14 of 18 All Outcomes

4/17 Early treatment study

Fujii et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.04.013 (Peer Reviewed)
Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients

Source PDF Share Tweet

Retrospective 41 favipiravir patients finding that early treatment was more successful.

Fujii et al., 4/17/2021, peer-reviewed, 10 authors.

All 18 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit